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Wnt signals at the base of mammalian crypts play a
pivotal role in intestinal stem cell (ISC) homeostasis,
whereas aberrant Wnt activation causes colon can-
cer. Precise control of Wnt signal strength is gov-
erned by a number of negative inhibitory mecha-
nisms acting at distinct levels of the cascade. Here,
we identify the Wnt negative regulatory role of
Sh3bp4 in the intestinal crypt. We show that the
loss of Sh3bp4 increases ISC and Paneth cell
numbers in murine intestine and accelerates ade-
noma development in Apcmin mice. Mechanistically,
human SH3BP4 inhibits Wnt signaling downstream
of b-catenin phosphorylation and ubiquitination.
This Wnt inhibitory role is dependent on the ZU5
domain of SH3BP4. We further demonstrate that
SH3BP4 is expressed at the perinuclear region to
restrict nuclear localization of b-catenin. Our data un-
cover the tumor-suppressive role of SH3BP4 that
functions as a negative feedback regulator of Wnt
signaling throughmodulating b-catenin’s subcellular
localization.INTRODUCTION
In mammalian intestine, Wnt ligands and the agonist R-spondin
are secreted at the crypt bottom to generate a Wnt gradient
radiating from stem cells to the trans-amplifying zone at the
crypt-villus junction. On the other hand, a number of negative
regulators acting at distinct levels of the cascade are present
to restrict Wnt signal at the crypt bottom. These include the pre-
viously reported Wnt inhibitors, such as AXIN2 (Jho et al., 2002),
RNF43 (Koo et al., 2012), and APCDD1 (Shimomura et al., 2010).
They are direct Wnt targets expressing in the Wnt-active intesti-
nal stem cell (ISC) region. These inhibitors negatively regulate the
pathway and are considered as tumor suppressors in various
human cancers (Giannakis et al., 2014; Cancer Genome Atlas
Network, 2012; Yan et al., 2017). These findings suggest that a
class of stem-cell-expressedWnt target genes function as nega-
tive-feedback regulators in the crypt to fine-tune Wnt/b-catenin2266 Cell Reports 26, 2266–2273, February 26, 2019 ª 2019 Francis
This is an open access article under the CC BY license (http://creativesignaling for ISC maintenance. Here, we describe the discovery
of SH3 domain-binding protein 4 (SH3BP4) that is expressed in
the Wnt-active intestinal crypt and negatively regulates Wnt/
b-catenin signaling.
SH3BP4 has been previously suggested as a potential tumor
suppressor gene in multiple human cancers, including breast,
renal, and non-small-cell lung cancers with a high frequency of
deletion (Kim et al., 2012). SH3BP4 plays a regulatory role in a
number of signaling pathways, including clathrin-mediated inter-
nalization of the transferrin receptor (TfR), fibroblast growth factor
receptor (FGFR) trafficking, and amino acid-RagGTPase-mecha-
nistic target of rapamycin 1 (mTORC1) signaling (Francavilla et al.,
2013; Kim et al., 2012; Tosoni et al., 2005). The role of SH3BP4 in
Wnt/b-catenin signaling and ISC homeostasis has never been
explored. In this study, we examine the role of SH3BP4 in
Wnt signal regulation in the context of intestine. The loss of
Sh3bp4 increases ISC numbers and augments tumorigenesis
with increasedWntactivity.Weshow thatSH3BP4negatively reg-
ulates Wnt signaling by modulating nuclear localization of b-cate-
nin. Our findings provide the mechanistic insight into the role of
Sh3bp4 in ISCs and cancer by regulatingWnt/b-catenin signaling.RESULTS
Expression of Sh3bp4 in the Wnt-Active Intestinal Crypt
We first characterized the expression of Sh3bp4 in the intestine.
qRT-PCR on mouse intestinal epithelium showed that Sh3bp4
was enriched in the crypt fraction similar to other ISC markers,
namely, Lgr5 and Olfm4 (Figure S1A). RNAscope in situ hybridi-
zation (ISH) further showed the crypt expression of Sh3bp4 in
both small intestine and colon (Figures 1A and 1B). RNAscope
co-staining analysis further revealed that Sh3bp4 was co-local-
ized with the ISC marker Lgr5 (Figure 1C), which was confirmed
by qRT-PCR of sorted Lgr5-GFP cells (Figure 1D).
Because Sh3bp4 is expressed in theWnt-active crypt bottom,
we asked if Sh3bp4 is regulated by Wnt signaling. RNAscope
analysis of Apcmin intestine showed upregulation of Sh3bp4
in adenomas with aberrant Wnt activation, suggesting that
Sh3bp4 expression is modulated by Wnt signaling (Figure 1E).
Consistently, expression of Sh3bp4 was also upregulated in
Apc mutant organoids (DAPC) generated by CRISPR targeting
(Figure 1F) (Novellasdemunt et al., 2017), as well as in
HEK293T cells upon Wnt3A stimulation (Figures S1B and S1C).Crick Institute.
commons.org/licenses/by/4.0/).
Figure 1. Sh3bp4 Is a Stem Cell-Expressed Wnt Target Gene
(A and B) Representative image of RNAscope ISH showing Sh3bp4 gene expression in small intestine (A) and colon (B).
(C) Representative RNAscope image showing co-localization of Lgr5 (red) and Sh3bp4 (blue) gene expression (indicated by black arrows).
(D) qRT-PCR showing fold change of stem-cell genes (Lgr5 and Olfm4) and Sh3bp4 in sorted Lgr5-GFP crypt cells from 6 biological replicates.
(E) Representative image of RNAscope ISH showing increased expression of Sh3bp4 in Apcmin adenomas.
(F) qPCR showing increased expression of Sh3bp4 in Apc-mutated organoids compared to WT organoids (n = 3).
Scale bars, 100 mm; insets, 50 mm. Data are represented as mean ± SD. ***p% 0.001, **p% 0.01. See also Figure S1.The Wnt-induced expression of SH3BP4 can be suppressed
upon Wnt inhibitor LF3 treatment (Figure S1C), suggesting that
SH3BP4 is Wnt transcriptional target. In addition, the upregu-
lated expression of SH3BP4 was also observed in human
colorectal cancer (CRC) tissues and the Wnt-activated CRC
cell lines (Figures S1D and S1E). Transcriptomic analysis of
human CRC patients further confirmed the increased expression
of SH3BP4 in tumor samples (Figure S1F) (Cancer Genome Atlas
Network, 2012).
To demonstrate SH3BP4 is transcriptionally regulated byWnt,
we analyzed the TCF7L2/TCF4 chromatin immunoprecipitation
sequencing (ChIP-seq) data generated from two different human
CRC cell lines, namely, Ls174T and HCT116 (ENCODE Project
Consortium, 2012; Hatzis et al., 2008). Multiple TCF4-binding
sites were identified upstream and throughout the gene locus
of SH3BP4 and were co-localized with the active enhancer re-
gions (H3K27Ac), suggesting that they are active TCF4-binding
motifs for gene transcription (Figure S1G). Together, these
data suggest that SH3BP4 is expressed in the Wnt-active intes-
tinal crypt and is transcriptionally activated by Wnt signaling.
Loss of Sh3bp4 Increases the Number of ISCs and
Paneth Cells
To investigate the functional role of SH3BP4 in intestinal
homeostasis, we crossed Sh3bp4fl/fl mice to VillinCreERT2
mice to generate intestine-specific conditional knockout
VillinCreERT2Sh3bp4fl/fl (Sh3bp4 cKO) animals (Figure S2A). RNA-
Scope analysis confirmed efficient loss of Sh3bp4 upon tamox-
ifen induction (Figure S2B). Sh3bp4 cKO intestine, 25 days post-
induction, showed increased expression of the stem cell markerand Wnt target Lgr5 when compared with Sh3bp4fl/fl control lit-
termates (hereafter named as wild-type [WT]) (Figures 2A–2D).
The increase in ISC number was further confirmed by another
stem cell marker,Olfm4 (Figures 2E–2H and 2M). Of note, the in-
crease in ISC number was consistently observed 3 months after
deletion ofSh3bp4 (Figures S2C andS2D). Because Paneth cells
constitute the niche for ISC maintenance (Sato et al., 2011), we
asked if the increase in ISC population was accompanied by
an increase in Paneth cell number. Indeed, increased Paneth
cell number was observed in Sh3bp4 cKO intestine, as revealed
by lysozyme staining, suggesting that the loss of Sh3bp4 results
in an expansion of ISCs and their niche (Figures 2I–2L and 2N).
We further assessed the clonogenicity of organoids derived
from WT and Sh3bp4 cKO intestinal crypts, which can be used
as a functional readout of stem cell numbers (Sato et al.,
2009). Sh3bp4-depleted organoids formed nearly two-fold
more clones than the WT ones, indicating that there are signifi-
cantly more stem cells in the mutant intestine (Figure 2O).
Besides the increase in the number of ISCs and Paneth cells,
no other gross morphological changes were observed in
Sh3bp4-depleted intestine (Figure S2E). The number of goblet
cells and enteroendocrine cells were comparable between
mutant and WT intestine, suggesting that differentiation is not
affected upon Sh3bp4 deletion (Figures S2F and S2G). Interest-
ingly, crypt proliferation was not altered despite the increase in
ISC numbers (Figures S2H–S2K). On the other hand, a significant
increase in the number of individual crypts per circumference
was observed in Sh3bp4 cKO intestine (Figures S2L–S2N). Pre-
vious studies have shown that crypt fission is a mechanism to
cope with accelerated mutant clonal expansion and epithelialCell Reports 26, 2266–2273, February 26, 2019 2267
Figure 2. Loss of Sh3bp4 Increases the Number of ISCs and Paneth Cells
(A–H) Histology analysis of WT (A, B, E, F, I, and J) and Sh3bp4 cKO (C, D, G, H, K, and L) intestine. Representative images of RNAscope ISH of the stem cell
markers Lgr5 (A–D) and Olfm4 (E–H).
(I–L) Immunohistochemistry of lysozyme representing Paneth cells. Images are representative of at least 6 animals analyzed per group. Scale bar, 100 mm. (B, D,
F, H, J, and L) High-magnification images of boxed area in (A, C, E, G, I, and K), respectively.
(M) Quantitation of number of Olfm4+ ISCs per crypt.
(N) Quantitation of number of lysozyme+ Paneth cells. Each dot represents the average number of cells per crypt per animal (determined from at least 30 crypts
per animal). Black bar shows the mean per group. n = 3 per group.
(O) Microscopy images of the organoids derived from WT and Sh3bp4 cKO animals. Number of organoids formed per 3,000 single cells.
Each dot represents the average of 3 triplicates per animal. Black bar indicates the mean per group. n = 5 animals/group. ***p% 0.001, **p% 0.01. See also
Figures S2 and S3.colonization (Nicholson et al., 2018; Snippert et al., 2014). Our
data suggest that the loss of Sh3bp4 leads to an expansion of
ISC compartment, which then causes accelerated crypt fission.2268 Cell Reports 26, 2266–2273, February 26, 2019SH3BP4 has previously been reported as a negative regulator
of mTOR1 signaling (Kim et al., 2012). We asked if the increase in
the number of ISCs upon Sh3bp4 loss is caused by upregulated
mTOR signaling. Sh3bp4 cKO andWT animals were treated with
vehicle or mTOR inhibitor rapamycin for 30 days, and intestinal
tissues were collected for histology analysis (Figure S3A).
Inhibition of mTOR signaling was confirmed by the loss of phos-
phorylation of the mTOR effector RPS6 (pS6) in both Sh3bp4
cKO and WT intestine (Figure S3B). Interestingly, suppression
of mTOR signaling did not rescue the ISC expansion phenotype
in Sh3bp4 cKO intestine, suggesting that the increase in ISC
numbers upon Sh3bp4 loss is independent of mTOR signaling
(Figures S3C–S3E).
Sh3bp4 Deletion Augments Tumorigenesis in Apcmin
Animals by EnhancingWnt Activation and Increasing the
Number of ISCs and Paneth Cells
Next, we examined if SH3BP4 plays a role in intestinal tumorigen-
esis.Sh3bp4cKOmicewerecrossed to the intestinal tumormodel
Apcminmice (ApcminSh3bp4cKO).Tamoxifenwasadministered to
the Apcmin and ApcminSh3bp4 cKO animals (n = 10/group) at
6 weeks old, and mice were sacrificed at predetermined humane
endpoints. Although Apcmin mice lived for 5–6 months (165 days
on average), ApcminSh3bp4 cKO mice started showing signs of
sickness much earlier by age 3–5 months (125 days on average)
(Figure 3A). ApcminSh3bp4 cKO mice (n = 13) exhibited more
than 2-fold increase in total adenoma numbers in small intestine
compared to control Apcmin littermates (n = 7) (Figures 3B and
3C). Most adenomas were low-grade dysplasias (LGD), whereas
ApcminSh3bp4 cKO mice had a moderate increase in the number
of adenomas with high-grade dysplasias (HGD) although not
significant (Figure S4A).
Because the loss of Sh3bp4 alone caused ISC expansion, we
further analyzed the stem cell marker Lgr5 expression in Apcmin
and ApcminSh3bp4 cKO adenomas. Consistent with the Sh3bp4
cKO phenotype, a significant increase in Lgr5-expressing stem
cells was observed in the ApcminSh3bp4 cKO adenomas (Figures
3D and S4B). We further asked if Wnt signaling is hyperactivated
uponSh3bp4 deletion. Increased nuclear localization of b-catenin
wasobserved inmostApcminSh3bp4cKOadenomas(FigureS4E).
This was accompanied by upregulated expression of Wnt targets
Axin2 andMyc inApcminSh3bp4 cKOadenomas (Figures 3E,S4F,
S4I, and S4J), suggesting that Wnt signaling is hyperactivated
upon Sh3bp4 deletion. The number of lysozyme+ Paneth cells
was also significantly increased inApcminSh3bp4 cKO adenomas
compared to the control Apcmin littermates (Figures 3F and S4C).
On the other hand, goblet cell number was reduced, suggesting
that differentiation is suppressed in Sh3bp4-depleted tumors
(Figure S4G). In addition, ApcminSh3bp4 cKO adenomas further
displayed increasedproliferation, as indicatedby5-ethynyl-20-de-
oxyuridine (EdU)+ cells, whereas apoptosis was not affected (Fig-
ures 3G, S4D, and S4H). Together, our findings indicate that the
loss of Sh3bp4 in an Apcmin background promotes intestinal
tumorigenesis by enhancing Wnt activation and expanding ISC
and Paneth cell populations.
SH3BP4 Inhibits Wnt Signaling by Modulating Nuclear
Localization of b-Catenin by the ZU5-Domain
To investigate how SH3BP4 regulates Wnt/b-catenin signaling,
we first generated SH3BP4 knockout (DSH3BP4) in HEK293T
cells by using the CRISPR/Cas9 system (Figures S5A andS5B). The loss of SH3BP4 resulted in a 2.5-fold increase in
Wnt3A-induced TOPFlash reporter transcriptional activity (Fig-
ure 4A), as well as an increase in active b-catenin protein levels
(Figure S5C). Consistently, significantly upregulated expression
of Wnt target genes AXIN2, CCND1, and MYC was detected in
DSH3BP4 cells compared to WT (Figure 4B). Next, we per-
formed ectopic expression of SH3BP4 in HEK293T cells and
found significant suppression of Wnt3A-induced TOPFlash ac-
tivity and the active b-catenin protein level (Figures 4C and
S5D). The results indicate that SH3BP4 negatively regulates
Wnt/b-catenin signaling. To understand how SH3BP4 regulates
the Wnt pathway, we examined the inhibitory effect of SH3BP4
on the signaling cascade at different subcellular levels by using
various Wnt activation models. In brief, Wnt activation was
achieved by (1) expressing a mutant form of the LRP6 receptor
lacking the extracellular domain (DN-LRP6) (Liu et al., 2003), (2)
expressing a constitutively active form of b-catenin (bCatS33Y),
(3) pharmacological inhibition of GSK3 activity by using
CHIR99021, or (4) inhibition of b-catenin ubiquitination upon
APC truncating mutation (HEK293TDAPC) (Novellasdemunt
et al., 2017). Interestingly, ectopically expressed SH3BP4 was
able to suppress Wnt activation mediated by a mutant receptor
(DN-LRP6) (Figure 4D), inhibition of b-catenin phosphorylation
(bCatS33Y and CHIR99021) (Figures 4E, S5E, and S5F), and
ubiquitination (HEK293TDAPC) (Figure S5G). The data support
the idea that SH3BP4 inhibits Wnt signaling downstream of
phosphorylation and ubiquitination of b-catenin.
To define the region of SH3BP4 that is important forWnt signal
inhibition, we generated different SH3BP4 truncating mutations
and a point mutant (SH3BP4W92A) destroying the first SH3
domain-specific interaction (Figure 4F) (Erpel et al., 1995; Tosoni
et al., 2005). Comparable protein expression levels were
observed across all mutant constructs (Figure S5H). We then
ectopically expressed WT or mutant SH3BP4 constructs in the
SH3BP4-deficient cells (DSH3BP4) and assessed the Wnt3A-
induced TOPFlash reporter activity. As expected, expression of
WT SH3BP4 readily suppressed the Wnt activation caused by
endogenous SH3BP4 depletion (Figure 4F). Similar to the WT
protein, most of the SH3BP4 mutants were also able to repress
Wnt activation except the ZU5-lacking mutant (SH3BP4DZU5),
suggesting that the Wnt inhibitory role of SH3BP4 is dependent
on the ZU5 domain (Figure 4F). This result was further confirmed
in the HEK293TDAPCWnt activatingmodel, where SH3BP4DZU5
failed to inhibit Wnt signaling induced by APC truncation
(Figure 4G). Together, we conclude that SH3BP4 inhibits Wnt
signaling downstream of b-catenin phosphorylation and ubiquiti-
nation and is dependent on its ZU5 domain.
Previous studies have shown that the SH3BP4 protein is local-
ized to the plasma membrane, perinuclear region, and clathrin-
coated vesicles (Kim and Kim, 2013; Kim et al., 2012; Tosoni
et al., 2005). In concordance with the previous studies, we
confirmed that WT SH3BP4 was predominantly expressed at
the perinuclear region (Figure 4H). We further confirmed the peri-
nuclear expression of SH3BP4 endogenously in the Wnt-acti-
vatedSW480CRCcells (FigureS5I). In contrast, theSH3BP4DZU5
mutant was localized to the plasma membrane and cytoplasm
instead, suggesting that the ZU5 domain is required for perinu-
clear localization of theSH3BP4protein (Figure 4H). Interestingly,Cell Reports 26, 2266–2273, February 26, 2019 2269
Figure 3. Sh3bp4 Deletion Augments Tumorigenesis in Apcmin Animals by Enhancing Wnt Signaling and ISC Numbers
(A) Kaplan-Meier survival analysis of Apcmin and ApcminSh3bp4 cKO mice. Loss of SH3BP4 was induced 6 weeks after birth (n = 10).
(B) Representative H&E-stained sections of small intestine from Apcmin (left) and ApcminSh3bp4 cKO (right) mice. Scale bar, 1 mm.
(C) Total number of adenomas in the intestine 2 months after induced SH3BP4 loss. Each dot represents the number of adenomas present per animal. Apcmin
(n = 7), ApcminSh3bp4 cKO (n = 13). Mean was indicated by black bars.
(D and E) Representative images of RNAscope ISH of stem cell and Wnt target genes Lgr5 (D) and Axin2 (E) in Apcmin (left) and ApcminSh3bp4 cKO (right) mice.
Magnifications of the boxed adenomas region are shown.
(F and G) Immunohistochemistry staining of lysozyme (F) and EdU (G) in the indicated tissues. Images are representative of at least 6 animals analyzed per group.
Scale bars, 100 mm. See also Figure S4.ectopic expression ofWT SH3BP4 inDAPC cells suppressed the
nuclear b-catenin level and enhanced perinuclear accumulation
of b-catenin that co-localized with SH3BP4 (Figure 4H). On the
other hand, the nuclear b-catenin level was not affected in
SH3BP4DZU5-expressing cells (Figure 4I). To validate the find-
ings, we further examined the b-catenin protein level in different2270 Cell Reports 26, 2266–2273, February 26, 2019subcellular fractions by using western blot analysis. Consistent
with the immunofluorescent data, expression of WT SH3BP4
(but not SH3BP4DZU5) significantly suppressed the b-catenin
level in the nuclear fraction (Figures 4J and 4K). Our results indi-
cate that SH3BP4 is expressed at the perinuclear region to con-
trol nuclear translocation of b-catenin. Deletion of ZU5 fails to
Figure 4. SH3BP4 Inhibits Wnt Signaling by Modulating Nuclear Translocation of b-Catenin by Its ZU5 Domain
(A) Relative Wnt3a-induced TOPFlash reporter activity in HEK293T wild-type and DSH3BP4 cells.
(B) qRT-PCR of Wnt target genes AXIN2, CCND1, and MYC in the indicated cells. Expression data are presented as fold induction normalized to b-actin.
(C–E) TOPFlash reporter activity upon ectopic expression of the indicated plasmids. Wnt signal is induced byWnt3A treatment (C), expression of DN-LRP6 (D), or
b-CatS33Y (E).
(F) Relative Wnt3a-induced TOPFlash reporter activity in WT (white bar) or DSH3BP4 (black bars) cells. Expression of WT or mutant SH3BP4 plasmids indicated
on the left. EV, empty vector.
(G) TOPFlash reporter activity upon ectopic expression of the indicated plasmids in HEK293TDAPC cells. Data represent average ± SD of at least three inde-
pendent experiments.
(H and I) Immunofluorescence of b-catenin (green), FLAG-SH3BP4 (red), and 40,6-diamidino-2-phenylindole (DAPI) (blue) in HEK293TDAPC cells. Expression of
WT SH3BP4 alters localization of b-catenin from nuclear to perinuclear membrane (arrow head) (H), whereas SH3BP4DZU5 does not affect b-catenin nuclear
localization (I). Scale bar, 100 mm.
(J) Western blot analysis of cytoplasmic-nuclear fractionation of HEK293TDAPC cells expressing empty-vector (EV), SH3BP4, or SH3BP4DZU5 by using indicated
antibodies.
(K) Quantitation of the b-catenin protein levels in (J). Fold change of b-catenin level was relative to tubulin (cytosol) or lamin A (nucleus) (n = 3).
Data represent mean ± SD. ***p% 0.001, **p% 0.01. See also Figure S5.
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localize SH3BP4 to the perinuclear region, thereby abrogating its
ability to regulate b-catenin nuclear shuttling.
DISCUSSION
In this study, we uncover the negative feedback role of SH3BP4
in Wnt signaling for intestinal homeostasis and tumorigenesis
(Figure S5J). Sh3bp4 is expressed in the intestinal crypt
under Wnt signal regulation. We show that SH3BP4 negatively
regulates Wnt signaling at the perinuclear region by restricting
b-catenin nuclear translocation by its ZU5 domain. Deletion of
Sh3bp4 increases the number of ISCs and Paneth cells, which
is independent of mTOR signaling. Loss of Sh3bp4 exacerbates
the Apcmin tumor phenotype through hyperactivation of Wnt
signaling, suggesting its tumor suppressive role in colorectal
cancer. Our findings highlight the crucial role of the negative
feedback mechanism in both stem cell and cancer.
Previous studies have identified several Wnt inhibitors, such
as AXIN2 and RNF43, that are expressed in the stem cell region
to repress Wnt signaling at the cytoplasmic destruction complex
and receptor levels, respectively (Jho et al., 2002; Koo et al.,
2012). Our current study unveils another crypt-expressed Wnt
inhibitor, SH3BP4, which contributes to the negative feedback
loop at the nuclear level. Regulation of the Wnt signal cascade
has been extensively characterized in the past, yet it remains
elusive how b-catenin nuclear translocation is controlled. Given
that b-catenin degradation is restricted to the cytoplasm, the
regulation of b-catenin nuclear export is, thus, likely to be an
important additional mechanism for Wnt signal regulation.
Several studies have previously reported the APC-mediated nu-
clear export of b-catenin (Henderson, 2000; Rosin-Arbesfeld
et al., 2000). Very recently, RAPGEF5 has further been reported
to facilitate nuclear transport of b-catenin by activating the nu-
clear GTPase (Griffin et al., 2018). Our current findings define
the ZU5-dependent role of SH3BP4 in negatively regulating
Wnt signaling by modulating nuclear transportation of b-catenin.
How SH3BP4 regulates b-catenin transportation at the perinu-
clear region remains to be determined. Interestingly, SH3BP4
has also been identified as a Rag GTPase-binding protein (Kim
et al., 2012). Further studies will be needed to address if the
role of SH3BP4 in regulating b-catenin nuclear transport is
dependent on RAPGEF5 and/or APC.
Our current data show that ZU5 is the critical domain for
modulating b-catenin nuclear localization. The ZU5 domain has
been found in a wide range of proteins and has been implicated
in protein-protein interactions. The ZU5 domain often exists
together with a C-terminal death domain in proteins related to
extracellular signal transduction, such as netrins (Reed et al.,
2004; Wang et al., 2009), and in scaffold proteins, such as ankyr-
ins (Ipsaro et al., 2009). The N-terminal SH3_1 domain of
SH3BP4 has been previously reported to interact with Rag
GTPases for mTOR inhibition (Kim et al., 2012), whereas its func-
tion is dispensable for Wnt signaling suppression. Together, the
data corroborate the notion that the regulatory role of SH3BP4 in
the Wnt pathway is independent of mTOR signaling. Whether
the ZU5 domain might interact with any of the previously re-
ported b-catenin nuclear transport proteins, such as APC and
RAPGEF5, deserves investigation.2272 Cell Reports 26, 2266–2273, February 26, 2019SH3BP4 is upregulated inmanyCRCs as a consequence of hy-
peractivation of Wnt signaling. Our current data suggest that
SH3BP4 is able to inhibitWnt signaling activated by APCor b-cat-
eninmutations,which raises questions aboutwhySH3BP4 fails to
suppress Wnt activity in CRC cells. One possible explanation is
that cancer cells may be addicted to the aberrant Wnt activation
induced by oncogenic mutations, such as APC, which outcom-
petes the negative feedback signals to maintain the pathological
Wnt activity. This perhaps is not so surprising considering that
the other well-knownWnt inhibitor AXIN2 is also highly expressed
in CRC cells. It is possible that such a negative feedback mecha-
nismplays a gate-keeping role for fine-tuning theWnt signal under
normal homeostasis, whereas the role of these Wnt inhibitors
might be less significant in cancer cells when Wnt activity passes
beyond the pathological threshold. An alternative explanation is
that the SH3BP4-mediated b-catenin nuclear shuttling mecha-
nismmight be inactivated in CRCs. In fact, inactivating mutations
or deletion of these Wnt inhibitors (e.g., AXIN2 and RNF43) have
been previously identified in human CRCs (Giannakis et al.,
2014;CancerGenomeAtlasNetwork, 2012;Yan et al., 2017), indi-
cating their tumor suppressive roles in cancer. Interestingly, dele-
tion and mutations of SH3BP4 have also been reported in various
cancers, including CRCs (Kim et al., 2012; Cancer Genome Atlas
Network, 2012), and are mutually exclusive with APC mutations
(Figure S5K). It is conceivable that SH3BP4 inactivation may
contribute to an alternative Wnt activating mechanism in certain
CRC subtypes, which could offer a new therapeutic strategy for
targeting Wnt signaling in cancer.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
All animal maintenance and regulated procedures were carried out according to Project License constraints (70/8560) and Home
Office guidelines and regulations. In accordance with the 3Rs, the smallest sample size was chosen that could give a significant dif-
ference. Sh3bp4fl/fl mouse was obtained from the International Mouse Strain Resource generated by the Wellcome Trust Sanger
Institute (Sh3bp4tm1a(EUCOMM)Wtsi), where two loxP sites were inserted flanking the critical exon 4. Sh3bp4fl/fl mice were crossed
to VillinCreERT2 (el Marjou et al., 2004) or Apcmin (Su et al., 1992). Animals of both sexes at age 6-7 weeks were used for the different
experimental conditions and harvested as indicated.
Tamoxifen was injected intraperitoneally for 3 consecutive days (1.5mg/10 g of mouse weight) from a 20mg/ml stock solution.
5-ethynyl-20deoxyuridine (EdU) (Life Technologies) was injected intraperitoneally (0.3mg/10 g ofmouseweight) from a 10mg/ml stock
solution. Rapamycin was injected intraperitoneally 60 days after the first tamoxifen injections. Mice were injected every other day
for 15 consecutive times with 10mg.Kg-1 of rapamycin. Rapamycin solution was prepared in ethanol at 50mg/ml and diluted 5%
Tween-80, 5% PEG400 in PBS to a final concentration of 2mg/ml.
METHOD DETAILS
Cell culture, transfection and TOPFlash assay
Cell lines were maintained in DMEM GlutaMAX (GIBCO) supplemented with 5% fetal bovine serum (FBS) (GIBCO) and 100 units/ml
penicillin (GIBCO) and 100 mg/ml streptomycin (GIBCO). HEK293TDAPC was generated previously by CRISPR targeting with trun-
cation at 1225a.a (APC4) (Novellasdemunt et al., 2017). All cell lines were incubated in a humidified atmosphere of 5% CO2 at 37C.
Cells were seeded in plates 24hrs before transfection and plasmids were transfected using polyethylenimine (Polysciences) accord-
ing to the manufacturer’s instructions. For the TOPFlash luciferase assay, cells were seeded at a density of 1x105 cells/well in a
24-well plate. The cells were then transfected with 200ng of TOPFlash or FopFlash plasmid constructs (Korinek et al., 1997). Trans-
fection efficiency was normalized against the co-transfected renilla luciferase activity (10ng/well). Wnt3A-conditioned medium was
added to the cells 24hrs post-transfection. Treated cells were lysed after 16hrs using luciferase lysis buffer (Promega), and luciferase
activity was measured using the Dual-Luciferase-reporter assay system (Promega) and analyzed in the microplate luminometer
(Centro XS3 LB960, Berthold Technologies).
For LF3 inhibitor treatment, cells were seeded in plates followed by treatment with Wnt3a+Rspondin-conditioned media or control
media. 16hr later, LF3 inhibitor treatment (30 uM) or DMSO was added to the media for an additional 8 hr.
Crypts/Villi fractionation and organoid culture
Small intestine was washed with cold PBS and cut into small pieces. Sequential incubations with 1mM EDTA for 20min at 4C were
performed. The resulting fractions of crypts and villi (in increasing purities) were passed through a 70mmcell strainer each time. Frac-
tions from above and below the strainer were collected and checked under the microscope for purity. Fractions of similar purity were
combined for RNA extraction, organoid culture or crypt cell sorting. For organoid culture, crypts were seeded in 20 ml of Cultrex
BME Type 2 RGF PathClear (Amsbio, 3533-010-02) in individual wells of a 24-well plate and cultured as previously described
(Sato et al., 2009). Apc mutant organoids (DAPC) was previously generated by CRIPSR targeting with truncation at 680aa (Apc5)
(Novellasdemunt et al., 2017).For sorting experiments, isolated crypts from Lgr5-GFP mice(Barker et al., 2007) were incubated inCell Reports 26, 2266–2273.e1–e4, February 26, 2019 e2
trypsin for 20 min at 37C, followed by trituration with a glass pipette. Dissociated cells were passed through cell strainer with a pore
size of 20 mm. GFPhi, GFPlow cells were sorted by flow cytometry. Unviable epithelial cells were determined by positive staining for
propidium iodide.
Plasmids and reagents
Full-length SH3BP4 was amplified by PCR from HEK293T cell cDNA. Briefly, 50ng of cDNA was amplified using Phusion High-
Fidelity PCR Master Mix (Biolabs). PCR products were cloned into pcDNA-FLAG plasmids using the In-Fusion DH Cloning Kit, ac-
cording to the manufacturer’s instructions. The SH3BP4 dead domain constructs were generated using the In-Fusion DH Cloning
Kit with primers specifically designed for each domain. Each primer contained a homology arm of 15 base pairs (bp). Primers
sequences are shown in Key Resources Table.
The constructs with site directed mutagenesis were generated by PCR of the original construct with the indicated mutagenic
primers PhusionHigh-Fidelity PCRMaster Mix was used and non-mutated parental DNA template was digestedwith the restriction
endonuclease DpnI.
CRISPR/Cas9 genome engineering
To generate SH3BP4 knock-out HEK293T cells, single guide RNA (sgRNA) was designed for specific target regions, as previously
described (Ran et al., 2013). HEK293T cells were transfected with plasmids encoding Cas9 and sgRNAs (PX459, #62988, Addgene,
a gift from Feng Zhang lab). SH3BP4 was targeted using the gRNA: 50gggcgaccatctctacgtct30. 48hrs after transfection, cells were
selected using 2mg/ml puromycin. Single, puromycin-resistant cells were selected and expanded for genomic DNA extraction.
The targeted locus was amplified and subcloned into a TA-cloning vector for cloning sequencing. Indel mutations were confirmed
by sequencing and loss of protein by western blot analysis.
Antibodies and western blot analysis
Cells were lysed in cold lysis buffer containing 150 mM NaCl, 30 mM Tris (pH 7.5), 1 mM EDTA, 1% Triton X-100, 10% Glycerol,
0.1 mM PMSF (phenylmethylsulfonyl fluoride), 0.5 mM DTT (dithiothreitol), protease inhibitor cocktail tablets (EDTA-free) (Roche),
and phosphatase inhibitor cocktail tablets (Roche). Lysates were pelleted for 30 min at 13200 rpm and supernatants kept for protein
quantification (Bradford assay). Equal amounts of cellular protein were resolved in 10% sodium dodecyl sulfate–polyacrylamide gels
(SDS-PAGE) and subsequently transferred to polyvinylidene difluoride (PVDF) membranes. Membranes were blocked using 5%milk
(OXOID) or 5% bovine serum (BSA) (Sigma) for phosphorylated proteins immunoblots, in Tris-buffered saline TBS (50mM Tris,
150mM NaCl, pH7.6) containing 0.1% Tween-20 (Sigma) (TBST) for 1 hour, and primary antibodies were added in blocking solution.
The following antibodies were used: Active b-catenin (1:1000, Millipore 05-665), b-catenin (1:1000, BD 610154), SH3BP4 (1:500,
Santa Cruz 393730), FLAG (1:1000, Sigma A2220), b-Actin (1:25000 Sigma A3854), Lamin A (1:1000, ab8980), Tubulin (1:5000,
T9026). Primary antibody incubations were carried out at 4C overnight. After washing with TBST, the appropriate HRP-conjugated
secondary was added (1:5000 in blocking buffer) for 2 hours at room temperature. Antibody binding was detected using chemilumi-
nescence ECL Prime Western Blotting Substrate (GE Healthcare).
Real-time quantitative RT-PCR
RNA was extracted according to the manufacturer’s instructions (QIAGEN RNAeasy). cDNA was prepared using Maxima first strand
cDNA synthesis kit (#1672, Thermo Scientific). Quantitative PCR detection was performed using iTaq SYBR Green Supermix. The
reaction mixture without template cDNA was run as a control. Expression was normalized to ACTIN as indicated and data were ex-
pressed as mean ± standard error. Primers sequences are indicated in Key Resource Table.
Immunofluorescence
Cells were grown on poly-L-lysine-coated (Sigma) glass coverslips in 12-well, fixed with 4% paraformaldehyde (PFA) for 15 min, and
permeabilised using 0.5% Triton X-100 in PBS for 10 min. Cells were blocked with 1%BSA in PBS for 1h before overnight incubation
with b-catenin (1:1000, BD 610154) and FLAG (1:1000, Sigma F7425) at 4C. Cells were washed three times with PBS and incubated
with secondary antibodies conjugated to Alexa Fluor 488 or 568 at room temperature for 1h in the dark. Cells were washed three
times with PBS and stained with DAPI for 10 min. Coverslips were washed another three times with PBS and were then mounted
with Aqua Poly/Mount (Polysciences). Images were taken using a Leica SPE confocal microscope. Each fluorophore was imaged
separately using 405, 488 and 561 channels. Confocal images were taken as Z stacks and processed using Fiji (Schindelin et al.,
2012).
Histology and Immunohistochemistry
Small intestine and colon tissues were fixed in 10% buffered formaldehyde for 16hrs time and embedded in paraffin. For staining,
4mm sections were de-paraffinized using xylene and rehydrated through a graded series of ethanol. Antigen retrieval was performed
for 20 min at high temperature in either 0.01M citrate buffer (pH6) or Tris-EDTA (10mM Tris base, 1mM EDTA solution, pH9), depend-
ing on the antibody. The following antibodies were used: Lysozyme (1:1500, DAKO a0099), Cleaved Caspase3 (1:900, RD AF835),
phospho-S6 (1:400, CS 2211), MYC (1:1500, 10828-1-AP), ChromograninA (1:1250, ab15160), b-catenin (1:4000, SC 7963), SH3BP4e3 Cell Reports 26, 2266–2273.e1–e4, February 26, 2019
(1:100, SC393730). Samples were blocked using 1% BSA and incubated overnight with the desired antibody or negative control at
4C. Finally, slides were incubated with the secondary antibody for 1h and washed three times with PBS. For colorimetric staining
with diaminobenzidine (DAB) slides were incubated with peroxidase substrate and mounted. Mice adenomas were graded by anal-
ysis of H&E stained sections by pathologist as follow: low grade dysplasia: mildly distorted glandular structures, branching villi and
tubular crypt proliferation, mild nuclear and cellular atypism, and intact basement membrane; high grade dysplasia: moderately or
severely distorted glandular structures with branching villi, severe nuclear and cellular atypism, increased mitotic figures, increased
atypical mucous retention. The human CRC sample was provided by the University College London Hospital. Ethical approval was
obtained from the UK Research Ethics Committee and informed consent was obtained from subjects.
RNAScope in situ hybridization
In situ hybridization (ISH) for Lgr5, Olfm4, Axin2 and Sh3bp4 was performed using the RNAscope FFPE assay kit (Advanced Cell
Diagnostics, Inc., Hayward, CA, USA) according to the manufacturer’s instructions. Briefly, 4mm formalin-fixed, paraffin-embedded
tissue sectionswere pre-treated with heat and protease digestion before hybridization with a target probe. Thereafter, an HRP-based
signal amplification systemwas hybridized to the target probes (Lgr5 ref #312171,Olfm4 ref #311831, Axin2 ref #400338, Sh3bp4 ref
#474731) before color development with 3,30-diaminobenzeidine tetrahydrochloride (DAB). Lgr5 staining quantification in Apcmin
adenomas was performed with the Segmentation Macro from ImageJ.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyzes were performed using GraphPad Prism8 software. Normal distribution of data was determined using the
D’Agostino and Pearson omnibus test. For parametric data, statistical significance was determined using a student’s unpaired,
two-tailed t test. In cases where more than two groups were being compared, then a one-way ANOVA was used. In instances where
the N was too small to determine normal distribution, or the data were non-parametric, a two-tailed Mann-Whitney U-test was used.
P values are represented as ***p% 0.001, **p% 0.01, *p% 0.05, non-significant (ns- p > 0.05).Cell Reports 26, 2266–2273.e1–e4, February 26, 2019 e4
